Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Dec 31, 2008

Title: Methods and Compositions for Improved Therapeutic Effects with siRNA
Number: 20080311040
Filed: March 5, 2008
Lead Inventor: David Arthur Berry, Flagship Ventures
The invention, the patent application’s abstract states, “relates to chemically modified, linked double-stranded RNA compositions comprising two or more double-stranded oligoribonucleotides linked by at least one linking moiety and methods of formulating and delivering such compositions to modulate gene expression through target-specific RNA co-interference. The compositions of the invention may optionally comprise a conjugation or a complex with one or more small molecule drugs, protein therapeutics, or other dsRNA molecules,” the abstract notes.
The invention “is directed at the methods of production for, methods of use of, and therapeutic utilities for RNAi co-interference therapy utilizing the compositions of the invention,” it adds.

Title: Bacteria-Mediated Gene Silencing
Number: 20080311081
Filed: June 13, 2008
Lead Inventor: Johannes Fruehauf, Cequent Pharmaceuticals
The patent application, its abstract states, claims “methods … for the delivery of one or more small interfering RNAs to a eukaryotic cell using a bacterium” or bacterial therapeutic particle. The application further claims “methods … for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating viral diseases and disorders,” the abstract adds. “The bacterium or BTP includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs … [and] vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.”

Title: Use of siRNAs in Organ Storage/Reperfusion Solutions
Number: 20080311552
Filed: Sept. 20, 2006 PCT Filed: Sept. 20. 2006
Inventor: Weiping Min, London Health Sciences Centre Research
The invention, the patent application’s abstract states, involves “the modification of organs, tissues, and cells with a storage/reperfusion solution comprising siRNAs specific for genes whose expression is associated with loss of viability or cell damage. The presence of siRNAs in the storage/reperfusion solution minimizes and/or prevents organ, tissue, and cell damage such that the organs, tissues, or cells can be used for in vivo transplantation. The invention is also directed generally to methods for maintaining organs, tissues, and cells in a viable state using the storage/reperfusion solution.”

Title: DNA Constructs for Specific Inhibition of Gene Expression by RNA Interference
Number: 20080311630
Filed: Nov. 22, 2006 PCT Filed: Nov. 22, 2006
Lead Inventor: Matthias Schroff, Mologen
“The invention relates to expression constructs for targeted inhibition of gene expression and methods for their production and which, after transfection thereof into eukaryotic cells, are suitable for inhibiting in a targeted manner these cells formation of defined proteins by RNA interference,” the patent application’s abstract states. The creation of these constructs involves “a three step method requiring no PCR steps and is carried out in one reaction vessel in a few hours,” the abstract adds.

Title: Combined Hairpin-Antisense Compositions and Methods for Modulating Expression
Number: 20080311658
Filed: March 20, 2008
Lead Inventor: John Skanklin, Brookhaven National Laboratory
The invention, the patent application’s abstract states, comprises “a nucleotide sequence that forms a stem and a loop, wherein the loop comprises a nucleotide sequence that modulates expression of a target … [and] the stem comprises a nucleotide sequence that modulates expression of a target.” The target, the abstract notes, is “modulated by the nucleotide sequence in the loop and the target modulated by the nucleotide sequence in the stem may be the same or different.”
According to the abstract, the application also claims ”vectors, methods of regulating target expression, methods of providing a cell, and methods of treating conditions comprising the nucleotide sequence.”

Title: Ribonucleic Acid Interference Molecules of Oryza Sativa
Number: 20080311659
Filed: July 31, 2008
Lead Inventor: Tien Huynh, IBM
According to the patent application’s abstract, the invention comprises specific RNAi sequences derived computationally from a genomic sequence corresponding to O. sativa. “Techniques are also provided for regulating gene expression,” the abstract states.

Title: Ribonucleic Acid Interference Molecules of Arabidopsis Thaliana
Number: 20080311661
Filed: July 31, 2008
Lead Inventor: Tien Huynh, IBM
According to the patent application’s abstract, the invention comprises specific RNAi sequences derived computationally from a genomic sequence corresponding to A. thaliana. “Techniques are also provided for regulating gene expression,” the abstract states.

Title: Microarray, System, and Method for Detecting, Identifying, and Quantitating microRNAs
Number: 20080312099
Filed: Feb. 15, 2007 PCT Filed: Feb. 15, 2007
Inventor: Eugenia Wang, University of Louisville Research Foundation
“MicroRNA microarrays useful for detecting, identifying, and quantitating miRNAs in a sample include oligonucleotide probes that specifically bind miRNAs,” the patent application’s abstract states. “Exemplary miRNA microarray can be specific for miRNAs of human, canine, mouse, rat, or another species.”

Title: Tetracycline-Dependent Regulation of RNA Interference
Number: 20080312171
Filed: May 31, 2006 PCT Filed: May 31, 2006
Lead Inventor: Jacques Mallet,Centre National De La Recherche Scientifique
The invention, the patent application’s abstract states, “relates to a tetracycline-dependent gene regulatory system or composition controlling the expression of a target gene in a cell and to methods using said system or composition. The … invention more specifically discloses compositions, vectors, and methods allowing tetracycline-controlled expression of short-hairpin RNAs, and demonstrates inducible, reversible and stable RNA interference using the same in a cell. The invention can be used to cause reversible control of the expression of any gene and may therefore find applications in the fields of mammalian, in particular human, genetics and molecular therapeutics, in cell and gene therapy, research, as well as in genetic studies using transgenic animals.”

Title: Targeted Transgenesis of Short Hairpin RNA Expression Cassettes Using Recombinase-Mediated Cassette Exchange
Number: 20080313747
Filed: July 7, 2005 PCT Filed: July 7, 2005
Lead Inventor: Heidrun Kern, Artemis Pharmaceuticals
According to the patent application’s abstract, “the invention provides a method for targeted transgenesis of short hairpin RNA expression cassettes using recombinase mediated cassette exchange. Suitable nucleotide acid sequences and vectors for the targeted transgenesis and recombinase mediated transgenesis are provided.”

Title: Production of Artificial microRNAs Using Synthetic microRNA Precursors
Number: 20080313773
Filed: May 8, 2008
Lead Inventor: Nam-Hai Chua, Rockefeller University
“The invention provides methods and compositions useful in target sequence suppression, target sequence validation, and target sequence down-regulation,” the patent application’s abstract states. “The invention provides polynucleotide constructs useful for producing artificial microRNA using synthetic amiRNA precursors.”

Title: Bioinformatically Detectable Group of Novel Regulatory Viral and Viral-Associated Oligonucleotides and Uses Thereof
Number: 20080318210
Filed: April 2, 2004
Lead Inventor: Isaac Bentwich, Rosetta Genomics
The invention, the patent application’s abstract states, “relates to a first group of novel viral and human-associated oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotides, and a second group of novel operon-like viral and human polynucleotides [called] … Genomic Record or GR polynucleotide.
“GAM oligonucleotides selectively inhibit translation of known target genes, many of which are known to be involved in various viral diseases,” the abstract notes, and the application claims “nucleic acid molecules … respectively encoding 15,484 GAM precursor oligonucleotides and 699 GR polynucleotides, as [well as] vectors and probes … comprising the nucleic acid molecules … methods and systems for detecting GAM oligonucleotides and GR polynucleotides and [their] specific functions and utilities, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.”

Title: Intranasal Delivery of Nucleic Acid Molecules
Number: 20080318895
Filed: July 2, 2008
Lead Inventor: Patty Lee, Yale University
The patent application, its abstract states, claims “aerosol delivery of nucleic acids to the lungs using viral vectors, polymers, surfactants, or excipients. … Compositions for intranasal administration … contain nucleic acids without viral or plasmid vectors and with little to no polymers, surfactants, or excipients. In one embodiment, the composition for intranasal delivery consists essentially of at least one nucleic acid and an aqueous solution.
“Suitable nucleic acids for intranasal delivery include, but are not limited to, dsDNA, dsRNA, ssDNA, ssRNA, short interfering RNA, microRNA, and antisense RNA,” the abstract adds. Also claimed in the application are “methods for treatment, diagnosis, or prevention of at least one symptom or manifestation of a lung disease … consisting of administration by intranasal delivery an effective amount of a composition containing a nucleic acid. The composition may be formulated as a liquid or aerosol or other acceptable formulation for intranasal administration.”

Title: Methods and Compositions for Controlling of Efficacy of RNA Silencing
Number: 20080318896
Filed: July 14, 2008
Lead Inventor: Phillip Zamore, University of Massachusetts Medical School
“Based at least in part on an understanding of the mechanisms by which small RNAs mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number of mismatches tolerated, the effect of the position of the mismatches, etc.,” the patent application’s abstract states. “Such rules are useful, in particular, in the design of improved RNAi-mediating agents which allow for more exact control of the efficacy of RNA silencing.”

Title: siRNA Targeting Protein Kinase N-3
Number: 20080319180
Filed: July 24, 2007
Lead Inventor: Anastasia Khvorova, Dharmacon
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PKN-3.”

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.